OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
OnKure Therapeutics (Nasdaq: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its upcoming participation in two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OnKure Therapeutics (Nasdaq: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its upcoming participation in two major investor conferences.
The company's President and CEO, Nicholas Saccomano, Ph.D., will participate in:
- A fireside chat at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025, at 4:20 p.m. ET, with a live audio webcast available online
- A fireside chat at the virtual Stifel Targeted Oncology Forum scheduled for April 8-9, 2025
The Leerink conference presentation will be accessible through a webcast link and the company's website, with replays available for 90 days post-event.
Details
News Market Reaction – OKUR
The recorded move for OKUR in the trading session of this news was +7.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences:
- A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this link and the Investors section of OnKure’s website at www.onkure.com. Following the event, a replay will be available on the OnKure website for at least 90 days.
- A fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually April 8-9, 2025. Additional information will be available on the OnKure website.
About OnKure Therapeutics
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure- and computational chemistry-driven drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.
Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.